HyTest and Affinity Life Sciences (AFF) have signed a licensing agreement that allows AFF to develop and commercialize a research use only ELISA-kit based on HyTest’s proprietary SES-BNP™ technology.
SES-BNP is a novel technology for detection of BNP and proBNP. The main advantage of this technology is that it is not sensitive to degradation of BNP in blood circulation which affects some of the other contemporary BNP assays.
“This is an important step in commercialization of our SES-BNP technology” comments Maria Severina (CEO, HyTest). She adds that “We have already signed a number of agreements with IVD companies. Now we are also able to enter the research market which is important in making SES-BNP the assay of choice for BNP detection. Affinity Life Sciences has extensive experience in immunoassay development and production and they have developed and manufactured numerous immunoassays utilized all over the world today. Our organizations share a focus on high quality products built on a strong scientific basis”.
Tod Gavron, President of Affinity is excited about the agreement, “It is an honor to partner with such a highly respected, worldwide organization like HyTest.” Gavron continued, “Developing such a unique assay for the BNP molecule will provide a very valuable tool for researchers.”
About Affinity Life Sciences:
Affinity Life Sciences, located in Amherst, NH is a cGMP and ISO 13485 compliant company dedicated to the specific needs of the biotechnology and pharmaceutical markets. Our 16,000 sqft facility can provide custom services including in vitro diagnostic kit production, lyophilization, cell culture production, and bioanalytical testing.
Learn more about Affinity Life Sciences at www.AffinityLifeSciences.com.
More information on SES-BNP can be found from here:
SES-BNP technology page